Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology

被引:13
作者
Ozcelik, Melike [1 ]
Seker, Mesut [2 ]
Eraslan, Emrah [3 ]
Koca, Sinan [4 ]
Yazilitas, Dogan [5 ]
Ercelep, Ozlem [1 ]
Ozaslan, Ersin [6 ]
Kaya, Serap [4 ]
Hacibekiroglu, Ilhan [7 ]
Menekse, Serkan [8 ]
Aksoy, Asude [9 ]
Taskoylu, Burcu Yapar [10 ]
Varol, Umut [11 ]
Arpaci, Erkan [12 ]
Ciltas, Aydin [13 ]
Oksuzoglu, Berna [3 ]
Zengin, Nurullah [5 ]
Gumus, Mahmut [2 ]
Aliustaoglu, Mehmet [1 ]
机构
[1] Kartal Dr Lutfi Kirdar Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey
[2] Bezmialem Vakif Univ, Sch Med, Dept Med Oncol, Istanbul, Turkey
[3] Ankara Oncol Educ & Res Hosp, Dept Med Oncol, Ankara, Turkey
[4] Marmara Univ, Pendik Educ & Res Hosp, Dept Med Oncol, Istanbul, Turkey
[5] Ankara Numune Training & Res Hosp, Dept Med Oncol, Ankara, Turkey
[6] Erciyes Univ, Sch Med, Dept Med Oncol, Kayseri, Turkey
[7] Trakya Univ, Sch Med, Dept Med Oncol, Edirne, Turkey
[8] Celal Bayar Univ, Sch Med, Dept Med Oncol, Manisa, Turkey
[9] Inonu Univ, Sch Med, Dept Med Oncol, Malatya, Turkey
[10] Pamukkale Univ, Sch Med, Dept Med Oncol, Denizli, Turkey
[11] Izmir Katip Celebi Univ, Atatruk Educ & Res Hosp, Dept Med Oncol, Izmir, Turkey
[12] Sakarya Univ, Sch Med, Dept Med Oncol, Sakarya, Turkey
[13] Ordu Univ, Sch Med, Dept Med Oncol, Ordu, Turkey
关键词
High-grade undifferentiated pleomorphic sarcoma; Malignant fibrous histiocytoma; Prognostic factors; Soft tissue sarcoma; MALIGNANT FIBROUS HISTIOCYTOMA; SOFT-TISSUE SARCOMAS; ADJUVANT CHEMOTHERAPY; SURGICAL-TREATMENT; EXTREMITIES; CLASSIFICATION; RECURRENCE; EXPRESSION; THERAPY; UPDATE;
D O I
10.1007/s13277-015-4359-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Most data on prognostic factors for patients with high-grade undifferentiated pleomorphic sarcoma (HGUPS) is obtained from analyses of soft tissue sarcomas. The purpose of this study was to evaluate the clinicopathologic features and their impact on outcomes specifically in patients diagnosed with HGUPS. In this multicenter trial, we retrospectively analyzed 112 patients who were diagnosed and treated at 12 different institutions in Turkey. We collected data concerning the patients, tumor characteristics, and treatment modalities. There were 69 males (61.6 %) and 43 females (38.4 %). Median age was 56 years (19-90). The most common anatomic site of tumor origin was the upper extremity. Pleomorphic variant was the predominant histological subtype. Median tumor size was 8.2 cm (0.6-30 cm). Tumors were mainly deeply seated (57.1 %). Fifty-seven patients (50.9 %) were stage II and the remainder were stage III at the time of diagnosis. Median follow-up was 30 months (2-160). The primary site of distant metastasis was the lung (73.5 %) and the second most common site was the liver (11.7 %). The 5-year overall survival, distant metastasis-free survival, and local recurrence-free survival rates were 56.3, 53.4, and 67.2 %, respectively. Multivariate analysis showed that Eastern Cooperative Oncology Group (ECOG) performance score of II (p = 0.033), deep tumor location (p = 0.000), and development of distant metastasis (p = 0.004) were negatively correlated with overall survival, and perioperative radiotherapy and negative microscopic margins were significant factors for local control rates (p = 0.000 for each). Deep tumor location (p = 0.003) was the only adverse factor related to distant metastasis-free survival. Deep tumor location, ECOG performance score of II, and development of distant metastasis carry a poor prognostic implication on overall survival. These will aid clinicians in predicting survival and treatment decision.
引用
收藏
页码:5231 / 5237
页数:7
相关论文
共 38 条
[1]  
Antman KH, 1997, SEMIN ONCOL, V24, P556
[2]   Malignant fibrous histiocytoma - A retrospective study of 109 cases [J].
Belal, A ;
Kandil, A ;
Allam, A ;
Khafaga, Y ;
El-Husseiny, G ;
El-Enbaby, A ;
Memon, M ;
Younge, D ;
Moreau, P ;
Gray, A ;
Schultz, H .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2002, 25 (01) :16-22
[3]  
Coindre JM, 2001, CANCER-AM CANCER SOC, V91, P1914, DOI 10.1002/1097-0142(20010515)91:10<1914::AID-CNCR1214>3.0.CO
[4]  
2-3
[5]   Expression profiling using tissue microarray in 211 malignant fibrous histiocytomas confirms the prognostic value of Ki-67 [J].
Engellau, J ;
Persson, A ;
Bendahl, PO ;
Åkerman, M ;
Domanski, HA ;
Bjerkehagen, B ;
Lilleng, P ;
Weide, J ;
Rydhohn, A ;
Alvegård, TA ;
Nilbert, M .
VIRCHOWS ARCHIV, 2004, 445 (03) :224-230
[6]   The evolving classification of soft tissue tumours: an update based on the new WHO classification [J].
Fletcher, CDM .
HISTOPATHOLOGY, 2006, 48 (01) :3-12
[7]   Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: Results of the Italian randomized cooperative trial [J].
Frustaci, S ;
Gherlinzoni, F ;
De Paoli, A ;
Bonetti, M ;
Azzarelli, A ;
Comandone, A ;
Olmi, P ;
Buonadonna, A ;
Pignatti, G ;
Barbieri, E ;
Apice, G ;
Zmerly, H ;
Serraino, D ;
Picci, P .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (05) :1238-1247
[8]   Treatment results and prognostic factors in patients with malignant fibrous histiocytoma [J].
Hsu, HC ;
Huang, EY ;
Wang, CJ .
ACTA ONCOLOGICA, 2004, 43 (06) :530-535
[9]   Prognostic Factors and Staging for Soft Tissue Sarcomas: An Update [J].
Jones, Natalie B. ;
Iwenofu, Hans ;
Scharschmidt, Thomas ;
Kraybill, William .
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2012, 21 (02) :187-+
[10]  
KEARNEY MM, 1980, CANCER-AM CANCER SOC, V45, P167, DOI 10.1002/1097-0142(19800101)45:1<167::AID-CNCR2820450127>3.0.CO